MNG265
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.734
- MYC_TARGETS_V2+0.501
- ADIPOGENESIS+0.419
- MYC_TARGETS_V1+0.384
- FATTY_ACID_METABOLISM+0.356
- UNFOLDED_PROTEIN_RESPONSE+0.349
- DNA_REPAIR+0.247
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.244
- PEROXISOME+0.243
- NOTCH_SIGNALING+0.224
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.457
- ALLOGRAFT_REJECTION-0.451
- INFLAMMATORY_RESPONSE-0.429
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.414
- IL6_JAK_STAT3_SIGNALING-0.365
- HEDGEHOG_SIGNALING-0.363
- INTERFERON_GAMMA_RESPONSE-0.359
- KRAS_SIGNALING_UP-0.338
- ANGIOGENESIS-0.321
- COMPLEMENT-0.312
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.877 |
| 2 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.872 |
| 3 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.869 |
| 4 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.867 |
| 5 | ERR2278847 | — | — | 0.864 |
| 6 | SRR6013506 | — | cohortA2 | 0.858 |
| 7 | ERR2278860 | — | — | 0.857 |
| 8 | MNG606 | — | — | 0.856 |
| 9 | SRR12475110 | — | — | 0.853 |
| 10 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.734 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.501 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.419 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.384 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.356 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.349 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.247 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.244 | Inavolisib | — uncovered |
| PEROXISOME | 0.243 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.224 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.196 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.163 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.116 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.113 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.047 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.037 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.017 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.007 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.005 | Remibrutinib | — uncovered |